<DOC>
	<DOC>NCT00257881</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.</brief_summary>
	<brief_title>Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Malignant solid tumor progressed, or no standard treatment available Tumor expression of Lewis Y antigen Cancer therapy within 28 days before enrollment Pregnant or breastfeeding women Unstable or serious concurrent medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Tumor</keyword>
</DOC>